ClinicalTrials.gg
RecruitingNCT06809114Updated Oct 13, 2026

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

A Phase 1 interventional study of AT03-65 in Solid Tumor, sponsored by Axcynsis Therapeutics Pte Ltd. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Axcynsis Therapeutics Pte Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 13, 2026Study contact changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors

Read the detailed description

This is a first-in-human (FIH), Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AT03-65 in adults with advanced solid tumors. AT03-65 is administered via intravenous infusion using an accelerated escalation method for the lower 3 dose level groups and the 3 + 3 escalation method is used in the subsequent dose level groups.

The study design is to identify the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) during 21-day cycle. One or more doses or regimens lower than or at the MTD may be selected for further evaluations under Dose Expansion to further evaluate the IMP and identify the RP2D.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

This is the only study on the registry with Axcynsis Therapeutics Pte Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old at the time of signing written form (ICF).
  2. (ECOG) Performance Status score of 0 or 1 at screening and on C1D1.
  3. documented, definitively diagnosed, advanced/ solid tumor that is resistant or to standard treatment, for which no further standard treatment is available, or the subject refuses or cannot tolerate standard therapy. Subjects must have according to (RECIST) v1.1.

3a) Monotherapy dose escalation study (Phase 1a):

  • Subjects (with documented CLDN6 expression after the lower three dose levels) will be enrolled, including but not limited to the following histological subtypes: serous or endometrioid ovarian cancer, primary peritoneal cancer or fallopian tube cancer, endometrial cancer, NSCLC, breast cancer, esophageal cancer, and gastric/GEJ cancer. There is no upper limit on the number of prior treatment regimens the subject may have received.

    3b) Monotherapy cohort expansion study (Phase 1b)

  • Subjects must meet the minimum requirement of CLDN6-expressing by IHC (cutoff value to be determined based on Phase Ia data and/or clinical studies of other CLDN6-targeting drugs), to be confirmed prior to enrollment.

Three cohorts will be involved:

Cohort 1: 24-30 subjects with advanced/metastatic CLDN6-expressing ovarian cancer, platinum resistant, refractory, or non-tolerant. Patients must have had one (or more) prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound, which may have included intraperitoneal therapy, high-dose therapy, consolidation, or extended therapy administered after completion of initial chemotherapy; patients must be considered platinum resistant or refractory according to standard Gynecologic Oncology Group (GOG) criteria, i.e., have had a treatment-free interval following platinum of 6 months or less, have persistent disease at the completion of primary platinum-based therapy or have progressed during platinum-based therapy, or be determined to be nontolerant after a recognized desensitization regimen.

Cohort 2: 24-30 subjects with advanced/metastatic CLDN6-expressing NSCLC. Subjects must have received at least one combination regimen (or platinum doublet where ). Patients with established driver mutations (epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], ROS proto-oncogene [ROS], mesenchymal epithelial transition factor [MET], rearranged during transfection [RET], B-Raf proto-oncogene, serine/threonine kinase [BRAF], and/or rat sarcoma [RAS]) must have progressed on standard of care for said mutation.

Cohort 3: 12 subjects with other advanced/metastatic CLDN6-expressing solid tumors who have exhausted options for standard of care therapies. There is no upper limit on the number of prior treatment regimens the subject may have received.

4) Subjects have fresh tumor sample or available for CLDN6 IHC (except for the lower three dose levels of Phase Ia). If archival block samples from multiple timepoints are available, the most recent one is preferred.

5) Subjects with good organ function

6) Has a (LVEF) ≥50% as determined by either an echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) within 28 days before the start of study treatment.

7) ≥3 months.

8) Male subjects with female partners of and female subjects of childbearing potential must agree to use a highly effective form of or avoid intercourse throughout the study period and for at least 6 months after the final administration of IMP. Males must agree not to freeze or donate sperm throughout the study period and for at least 6 months after final administration of IMP. Investigators will advise male subjects on the conservation of sperm prior to study treatment. Females must agree not to donate or retrieve ova for own use throughout the study period and for at least 6 months after final administration of IMP.

Exclusion criteria

Exclusion Criteria:

  1. Subjects previously received or is currently receiving any systemic anti-cancer therapy within 4 weeks or 5xT(1/2) if 5xT(1/2) of the drug/therapy used by the subject is confirmed to be \< 4 weeks, 5xT(1/2) shall prevail] - prior to first dose of IMP
  2. Not yet recovered to Grade 1 or baseline for treatment-related toxicities related to previous treatment with the exception of alopecia. The recovery time after surgery was less than 28 days
  3. Subjects with congenital or acquired cardiovascular diseases.
  4. Presence of other active invasive cancers other than the one treated in this study within 5 years prior to screening, except appropriately treated BCC of the skin or in situ carcinoma of uterine cervix, or other local tumors considered cured by local treatment
  5. Subjects with severe or uncontrolled systemic disease, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, or active infection requiring intravenous injection (IV) of antibiotics, antivirals or antifungals
  6. Subjects with medical history of clinically significant lung disease or who are suspected to have these disease by imagining at screening
  7. within 4 weeks prior to first dose of IMP
  8. Presence of active or untreated to central nervous system or meninges or other evidence showing that metastatic lesions in central nervous system or meninges that have not yet been controlled at screening. Note: Subjects with central nervous system or meningeal metastases who are free of neurological symptoms not managed with and stable by imagining 28 days after treatment prior to the first dose may be considered for enrollment
  9. Presence of .
  10. Prior treatment with any ADC targeting CLDN6. Note: Prior treatment with immune engagers targeting CLDN6 is permitted.
  11. Subjects who have received prior or autologous bone marrow transplants.
  12. Subjects who are pregnant (as confirmed by pregnancy tests performed within 7 days before enrollment) or planning to become pregnant.
  13. Subjects who have received moderate or strong cytochrome P450 (CYP) 2C8 or inhibitors or inducers, or P-glycoprotein (P-gp) inhibitors within 14 days prior to the first dose or cannot be discontinued during the study.
  14. The investigator considers that the patient is not suitable for participating in this study (e.g.,IMP is not in the best interest of patient, patients with mental disorder, patients with poor compliance, etc.).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    AT03-65 Dose Escalation and Dose Expansion

    Subjects will receive AT03-65 via intravenous (IV) infusion on Day 1 of a 21-Day treatment cycle.

    Drug: AT03-65

Interventions

  • DrugAT03-65

    Treatment will continue until disease progression, unacceptable toxicity, subject withdrawal of consent or death.

    Also known as: AT03-65 Antibody Drug Conjugate

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of AT03-65

    The MTD is defined as the highest dose with an observed incidence of DLT in no more than one out of six patients treated at a particular dose level.

    Time frame: Up to 21 days

  2. Dose-limiting toxicity (DLT)

    DLT refers to AEs that occurred during DLT observation period in dose escalation study, excluding toxicities clearly due to the underlying disease or extraneous causes.

    Time frame: Up to 21 days

Secondary outcomes

  1. Determine levels of AT03-65 and its constituents over time in plasma

    Assess PK concentration of AT03-65 in peripheral blood

    Time frame: Maximum 2 years

  2. Evaluate changes in circulating tumor DNA in plasma

    Assess PD markers related to AT03-65 in peripheral blood

    Time frame: Maximum 2 years

  3. Determine the presence of antibodies to AT03-65 at different times in plasma

    Assess immunogenicity concentration in peripheral blood

    Time frame: Maximum 2 years

  4. Assessment of Overall Response Rate (ORR) in subjects with advanced / metastatic solid tumors

    Percentage of subjects whose best response is observed to be CR or PR throughout the study as assessed by local radiological assessment made by investigator according to RECIST V1.1

    Time frame: Maximum 2 years

  5. Determine the expression level of CLDN6 in tumor samples

    Assess the presence and expression level of CLDN6 in tumor samples

    Time frame: Maximum 2 years

  6. Progress-Free Survival (PFS) of treatment in subjects with advanced / metastatic solid tumors

    PFS as assessed by Local Investigators according to RECIST V1.1

    Time frame: Maximum 2 years

  7. Assessment of Disease Control Rate (DCR)in subjects with advanced / metastatic solid tumors

    Percentage of subjects with best overall response of CR, PR and SD as assessed per RECIST v1.1

    Time frame: Maximum 2 years

  8. Assessment of Duration of Response (DOR) of treatment in patients with solid tumor

    DOR as assessed by Local Investigators according to the RECIST V1.1

    Time frame: Maximum 2 years

  9. Assessment of Overall Survival (OS) of treatment in subjects with advanced / metastatic solid tumors

    OS as assessed as duration from first dose of IMP to death

    Time frame: Maximum 2 years

  10. Assessment of Clinical Benefit Rate (CBR)in subjects with advanced / metastatic solid tumors

    Percentage of subjects whose best response is observed to be CR, PR or SD

    Time frame: Maximum 2 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data generated by this study will be considered confidential by the Investigator, except to the extent that it is included in a publication. The general strategy regarding publication of the study will be mutually agreed upon by the Investigator and Sponsor. The Sponsor reserves the right to manage the publication of all study results. The Investigator agrees that oral and written communication to third parties of any procedures or results from the study is subject to prior written consent of the Sponsor. Presentation material and/or manuscript(s) for publication will be reviewed by the Sponsor prior to submission for publication. Alterations in the material will only be made in agreement between the Investigator and the Sponsor

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Feb 5, 2025
StartActual
Jan 14, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Aug 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • SCRI HealthOne · Denver, United States
  • YALE · New Haven, United States
  • Medical University of South Carolina MUSC · Charleston, United States
Oct 13, 2026
Contact
Study contact changed: h•••@axcynsis.com · •••6856→h•••@axcynsis.com · •••6856. See the current contact
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    3 sites added
    Show 3 added (3 United States)
    • SCRI HealthOne · Denver, United States
    • YALE · New Haven, United States
    • Medical University of South Carolina MUSC · Charleston, United States
    Contact Study contact changed: h•••@axcynsis.com · •••6856→h•••@axcynsis.com · •••6856. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06809114
Lead sponsor
Axcynsis Therapeutics Pte Ltd
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Jan 14, 2026
Primary completion
Dec 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Chief Medical Advisor
Contact
h.gardner@axcynsis.com
7813756856
Maria DeAssis
Contact
maria.deassis@axcynsis.com
6178208329

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion